← Back to Clinical Trials
Recruiting Phase 2 NCT03908736

NCT03908736 Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03908736
Status Recruiting
Phase Phase 2
Sponsor University of New Mexico
Condition DNA Damage
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2019-05-19
Primary Completion 2027-07

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 64 Years
Study Type INTERVENTIONAL
Interventions
Zinc Picolinate 15 Mg

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 100 participants in total. It began in 2019-05-19 with a primary completion date of 2027-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a study to assess the effect of dietary zinc supplementation to mitigate biomarkers of metal toxicity in exposed tribal populations.

Eligibility Criteria

Inclusion Criteria: * Men or women between the ages of 21 and 64 years of age * Lives in or near the participating communities of Blue Gap-Tachee Arizona or Red Water Pond Road Community New Mexico * Willing to provide blood and urine samples * Willing to attend study visits on scheduled dates * Willing to take a daily zinc supplement Exclusion Criteria: * Women who are pregnant or nursing or women who plan to become pregnant during the course of the study. * Individuals who have self-reported diabetes, report that they are undergoing treatment for diabetes, or are currently taking medication for diabetes. * Known or suspected allergy to zinc. * Individuals previously diagnosed with syndromes of copper homeostasis (Menkes disease or Wilsons disease). * Individuals consuming zinc supplements or multivitamins and are unwilling to stop for the duration of the study.

Contact & Investigator

Central Contact

Laurie G Hudson, PhD

✉ lhudson@salud.unm.edu

📞 505-272-2482

Frequently Asked Questions

Who can join the NCT03908736 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 64 Years, studying DNA Damage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT03908736 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT03908736 currently recruiting?

Yes, NCT03908736 is actively recruiting participants. Contact the research team at lhudson@salud.unm.edu for enrollment information.

Where is the NCT03908736 trial being conducted?

This trial is being conducted at Albuquerque, United States.

Who is sponsoring the NCT03908736 clinical trial?

NCT03908736 is sponsored by University of New Mexico. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology